Is There a Place for Chimeric Antigen Receptor–T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?

Chimeric antigen receptor–T (CAR‐T) cell therapy is based on specific targeting of tumor antigens, leading to lysis and destruction of tumor cells. The high potency of CAR‐T cells in the management of B cell malignancies has been demonstrated. Following the success of this therapeutic strategy, new CAR‐T cell–derived constructs that have the ability to eradicate pathogenic B cells or restore tolerance have been developed. The present review...